Actively Recruiting
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Led by Sparrow Pharmaceuticals · Updated on 2025-12-23
16
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
CONDITIONS
Official Title
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female participants with stable moderate renal impairment (estimated glomerular filtration rate [eGFR]: 30 to <60 mL/min)
- Matched control participants with normal renal function (eGFR: 290 mL/min) matched by sex, age, and weight
You will not qualify if you...
- Participants with medical conditions, medications, or procedures that increase safety risk or are unsuitable for the trial
- Participants with clinically significant abnormal 12-lead electrocardiogram (ECG), vital signs, or laboratory test results at screening and check-in
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here